Ozanimod: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Ozanimod appears in the FDA drug-label database. Marketed as ZEPOSIA 7-Day Starter Pack, ZEPOSIA, ZEPOSIA Starter Kit.
FDA-approved use
ZEPOSIA is indicated for the treatment of: relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. moderately to severely active ulcerative colitis (UC) in adults. ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ) Moderately to severely active ulcerative colitis (UC) in adults. ( 1 )
Phase breakdown
Conditions being studied
Recruiting trials involving Ozanimod
- A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
- A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
- Ozanimod in Patients With Alzheimer's Disease
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
- Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Common questions
Is Ozanimod FDA-approved?
Yes, marketed as ZEPOSIA 7-Day Starter Pack, ZEPOSIA, ZEPOSIA Starter Kit.
How many recruiting trials involve Ozanimod?
7 recruiting trials across 9 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.